Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Blast Crisis 1

Interventions

Gemcitabine 97130-nm albumin-bound paclitaxel 47Albumin-Bound Paclitaxel 36Oxaliplatin 27Fluorouracil 26Capecitabine 20Taxes 19Leucovorin 19pembrolizumab 18Cyclophosphamide 18Irinotecan 16Bevacizumab 12fludarabine 11Nivolumab 11Cetuximab 11Cisplatin 10durvalumab 8Radiotherapy 8spartalizumab 7aldesleukin 7Erlotinib Hydrochloride 7Drug Therapy 7avelumab 6Radiosurgery 6Paclitaxel 6irinotecan sucrosofate 5folfirinox 5Ipilimumab 5Injections 5ALT-803 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Pancreatic Neoplasms × vatalanib × Clear all
NCT00185588 2014-09-15

Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer

Stanford University

Phase 1/2 Completed
33 enrolled 10 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡